Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFA14A
Source: 0000930413-25-001275
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFA14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934</div>

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐Preliminary Proxy Statement

☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐Definitive Proxy Statement

☒Definitive Additional Materials

☐Soliciting Material Pursuant to §240.14a-12

<div align='center'>Dynavax Technologies Corporation

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

☒No fee required.

☐Fee paid previously with preliminary materials.

☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11.

This Schedule 14A filing consists of the following
press release relating to a letter distributed by Dynavax Technologies Corporation (the “Company”) to its stockholders in
connection with the Company’s 2025 Annual Meeting of Stockholders. The press release was first used or made available on April 17,
2025.

FOR IMMEDIATE RELEASE

<div align='center'>Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders

Urges Stockholders to Vote “FOR”All Four Dynavax Director Nominees on the GOLDProxy Card

Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy and Meaningful Board Refreshment

Underscores Deep Track’s Value Destructive, Short-Term Focus and Unnecessary Proxy Contest</div>

EMERYVILLE, Calif., April 17, 2025– Dynavax Technologies
Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company
developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities
and Exchange Commission (“SEC”) in connection with its upcoming Annual Meeting of Stockholders scheduled to be held
on June 11, 2025. Stockholders of record as of April